Insider transactions
David Malcom Rodman, the Chief Medical Officer of Mineralys Therapeutics, Inc. (NASDAQ: MLYS), completed a pair of linked equity transactions on April 17, 2026. Under a Rule 10b5-1 trading plan adopted on October 6, 2025, Rodman exercised options to acquire 416 shares and then sold the same number of shares.
The option exercise purchased 416 shares of Mineralys common stock at an exercise price of $15.44 per share, for a total cash outlay of $6,423. Immediately following that, Rodman sold 416 shares of the common stock at $31.33 per share, generating proceeds of $13,033.
After recording these moves, Rodman directly holds 69,792 shares of Mineralys common stock.
Grant and vesting mechanics
The options exercised were part of a grant with a staged vesting schedule: 25% of the grant vested on the first anniversary of the grant date, and the remaining portion vests in 36 substantially equal monthly installments. Both the acquisition by exercise and the subsequent sale were executed under the previously mentioned 10b5-1 plan.
Stock performance and valuation context
MLYS shares have recorded a 117% gain over the last 12 months, according to InvestingPro data. On the day of the filing, the stock traded at $28.78, which is below the $31.33 per-share price received by Rodman in his sale transaction. The article notes analysis that suggests the company appears undervalued at current market levels and points readers to a Pro Research Report for further valuation and performance metrics across MLYS and other U.S. equities.
Recent operational and analyst developments
Mineralys reported fourth-quarter 2025 earnings that exceeded consensus estimates, delivering an EPS of -0.4 versus a forecasted -0.94. Despite the earnings surprise, the company faces investor attention regarding rising general and administrative expenses.
On the analyst front, BofA Securities raised its price target for Mineralys to $51.00 while maintaining a Buy rating, citing progress in the clinical development of lorundrostat for uncontrolled hypertension. Stifel reiterated a Buy rating with a $52.00 price target, pointing to the company’s preparations for a potential product launch contingent on FDA acceptance of the New Drug Application. In contrast, Jefferies lowered its price target to $30.00 and kept a Hold rating, noting company considerations around strategies to maximize the value of lorundrostat.
Corporate appointment
Mineralys also announced the appointment of Jeffrey A. Munsie as Chief Legal Officer. The company described Munsie as bringing nearly 25 years of legal experience in the biopharmaceutical industry.
Takeaway
The filings show a routine exercise-and-sale executed under a pre-established trading plan that modestly monetized in-the-money options. At the same time, the company reports operational progress and maintains active analyst coverage with a range of valuations, while investors weigh cost trends in general and administrative spending.